Uncategorized

AlzeCure Gets an Abstract on Non-Opioid ACD440 for Neuropathic Pain Accepted at the EFIC 2023 Conference

AlzeCure Pharma AB announced that an abstract on ACD440, the leading non-opioid drug candidate in the Painless platform, has been accepted for presentation at the annual international pain conference EFIC, European Pain Federation, which this year is being held in Budapest, Hungary, on September 20-22.

AlzeCure Gets an Abstract on Non-Opioid ACD440 for Neuropathic Pain Accepted at the EFIC 2023 Conference Read More »

Nona Biosciences and Washington University Join Forces to Tackle Emerging RNA Viruses

Nona Biosciences announced it has entered into a collaboration agreement with Michael S. Diamond, MD, PhD, of Washington University in St. Louis to discover viral targets for which few or no human monoclonal antibodies currently exist, such as western equine encephalitis virus, rabies and severe fever with thrombocytopenia syndrome virus.

Nona Biosciences and Washington University Join Forces to Tackle Emerging RNA Viruses Read More »

Modalis Therapeutics to Present Data Supporting of Development of Transformative Epigenetic Editing Medicines for the Treatment of a Type of Muscular Dystrophy at the ASGCT Annual Meeting

Modalis Therapeutics Corporation announced that the abstract has been accepted for a presentation in the late-breaking session at the 26th Annual Meeting of The American Society of Gene & Cell Therapy, being held in Los Angeles CA on May 16-20, 2023.

Modalis Therapeutics to Present Data Supporting of Development of Transformative Epigenetic Editing Medicines for the Treatment of a Type of Muscular Dystrophy at the ASGCT Annual Meeting Read More »

Scroll to Top